,,iv  #aag? ,,congress  #a/ ,session    
,h4 ,,res4 #dhd  ,,9 ,,! ,,h\se ,,(     
,,repres5tatives  ,june #ag1 #bjba,mrs4 
,mill]-,meeks 7= h]self1 ,mrs4 ,fis*ba*1
 ,mr4 ,jordan1 ,mr4 ,norman1 ,mr4       
,gibbs1 ,mr4 ,van ,drew1 ,mr4 ,budd1    
,mr4 ,hice ( ,georgia1 ,mr4 ,gre5 (     
,t5nessee1 ,mrs4 ,h9son1 ,mr4 ,ru!r=d1  
,mrs4 ,wagn]1 ,ms4 ,mace1 ,mr4 ,duncan1 
,mr4 ,ow5s1 ,mr4 ,c4 ,scott ,frankl9 (  
,florida1 ,mr4 ,bur*ett1 ,mr4 ,hudson1  
,ms4 ,malliotakis1 ,mr4 ,emm]1 & ,ms4   
,*5ey7 submitt$ ! foll[+ resolution2 :i*
 0 ref]r$ to ! ,committee on ! ,judici>y
  ,,resolution  ,express+ ! s5se ( !    
,h\se ( ,repres5tatives t ! ,unit$      
,/ates %\ld n waive intellectual prop]ty
 rights relat+ to ,,covid-#ai vacc9es or
 treatm5ts4  ,:]eas build+ on decades ( 
rese>* & 9 conjunction ) ,op]ation ,w>p 
,spe$1 ! ,unit$ ,/ates ph>maceutical    
indu/ry successfully develop$ ?ree      
incr$ibly effective ,,covid-#ai vacc9es 
to date1 ) a f\r? vacc9e curr5tly       
und]go+ cl9ical trials2 ,:]eas ^!       

vacc9es are ! mo/ respect$1 mo/ s\ght   
aft] vacc9es 9 ! _w due to _!           
exceptional efficacy & safety1 :i* is   
due to bo? ! pa9/ak+ "w & inve/m5t dur+ 
developm5t z well z ! dilig5t ef=ts ( ! 
,unit$ ,/ates ph>maceutical indu/ry to  
qualify & ov]see _w-class manufactur+   
facilities to produce ! vacc9es2 ,:]eas 
intellectual prop]ty protections are    
vital to inc5tivize innovation1 includ+ 
! innovations t directly l$ to !        
,,covid-#ai vacc9es & may revolutionize 
future vacc9e developm5t ef=ts2 & ,:]eas
 intellectual prop]ty protections h n   
contribut$ significantly to %ortages (  
,,covid-#ai vacc9es or _h a significant 
effect on ! pace ( vacc9ations1 bo? (   
:i* are pr$om9antly dep5d5t on logi/ical
 *all5ges1 raw mat]ial %ortages1 & o!r  
factors3 ,n[1 !re=e1 be x t x is ! s5se 
( ! ,h\se ( ,repres5tatives t-- 7#a7 !  
policy ( ! ,unit$ ,/ates %\ld n be to   
waive valid intellectual prop]ty        
protections = ,,covid-#ai vacc9es or    
treatm5ts1 relat$ manufactur+ processes 

or te*nology1 te*nology plat=ms us$ to  
develop ,,covid-#ai vacc9es or o!r      
m$ic9es1 or o!r relat$ innovations2 &   
7#b7 ! policy ( ! ,unit$ ,/ates %\ld n  
be to /rip innovators ( valid           
intellectual prop]ty protections because
 x w\ld und]m9e innovation1 weak5 !     
competitiv5ess ( ,unit$ ,/ates          
bus9esses1 & damage our ability to      
respond to future p&emics4